Hospital Pequeno Príncipe, Curitiba, Paraná, Brazil.
Hospital de Clínicas da Universidade Federal do Paraná, Curitiba, Paraná, Brazil.
Neurol Sci. 2019 Feb;40(2):351-356. doi: 10.1007/s10072-018-3648-z. Epub 2018 Nov 20.
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an immune-mediated disease of the central nervous system (CNS). The aim of this study was to describe the variability of clinical presentation in anti-NMDAR encephalitis, treatment and outcomes in a case series of children and adolescents.
Retrospectively analyse patients diagnosed with anti-NMDAR encephalitis, from 2010 to 2018.
The study population consisted of nine children with anti-NMDAR encephalitis from southern Brazil, six females and three males, aged 5 months to 16 years (mean 5 years). The time of follow-up varied between 1 and 7 years, with a mean of 3 years. The most frequent first manifestation consisted of seizures. All patients described had psychiatric symptoms and a wide spectrum of neurologic findings. Five patients had unilateral symptoms. Magnetic resonance imaging and electroencephalogram were normal in most patients. Cerebrospinal fluid pleocytosis occurred in five patients. All patients were administered immunoglobulin and/or steroids. Seven patients (78%) required cyclophosphamide and/or rituximab. Almost half of the patients fully recovered from all symptoms.
A wide variety of symptoms were observed in this study and, although unilateral symptoms are rarely reported in the literature, a high frequency was observed among Brazilian children. Alternatives to first-line therapy should be considered in patients with clinical suspicion, even if they have not had a good response with first-line therapy.
抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎是一种中枢神经系统(CNS)的免疫介导性疾病。本研究旨在描述抗 NMDAR 脑炎在儿童和青少年病例系列中的临床表现、治疗和结局的可变性。
回顾性分析 2010 年至 2018 年间诊断为抗 NMDAR 脑炎的患者。
研究人群包括来自巴西南部的 9 例抗 NMDAR 脑炎患儿,6 例为女性,3 例为男性,年龄 5 个月至 16 岁(平均 5 岁)。随访时间从 1 至 7 年不等,平均 3 年。最常见的首发表现为癫痫发作。所有患者均有精神症状和广泛的神经系统表现。5 例患者有单侧症状。大多数患者的磁共振成像和脑电图正常。5 例患者的脑脊液有白细胞增多。所有患者均接受免疫球蛋白和/或类固醇治疗。7 例(78%)患者需要环磷酰胺和/或利妥昔单抗。近一半的患者完全从所有症状中恢复。
本研究观察到了各种各样的症状,尽管单侧症状在文献中很少报道,但在巴西儿童中观察到的频率较高。即使一线治疗没有良好的反应,也应考虑在有临床怀疑的患者中使用一线治疗以外的替代方法。